Drug Trial Radar · NCT00151892
Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Jun 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
829
Actual
Start
Apr 8, 2005
Primary completion
Sep 7, 2009
Study completion Sep 7, 2009
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 9, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ulcerative colitis is a disease of the large bowel (colon) and rectum in which the lining of the bowel becomes red and swollen. Over time, patients with this disease may experience acute episodes of diarrhea, rectal bleeding and abdominal pain followed by periods of time without disease symptoms. 5-ASA drugs are a standard treatment for ulcerative colitis. Mesalazine is an experimental drug designed to gradually release 5-ASA into the areas of large bowel associated with ulcerative colitis. This study will test the safety and efficacy of mesalazine in keeping ulcerative colitis in remission.
Conditions
- Ulcerative Colitis
Interventions
SPD476Drug
2.4 g/day Once Daily (QD)
AsacolDrug
1.6g/day administered 800 mg Twice Daily (BID)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Endoscopic Remission of Ulcerative Colitis (UC) at 6 MonthsTime frame: 6 Months
Locations
142 sites in 28 countries. Site status is shown where the registry gives one.
Birmingham Gastroenterology Associates
Birmingham, Alabama
Connecticut Gastroenterology Institute
Bristol, Connecticut
Washington Gastroenterology
Washington D.C., District of Columbia
Southern Clinical Research Consultants
Hollywood, Florida
Boorland-Groover Clinic
Jacksonville, Florida
United Medical Research
New Smyrna Beach, Florida
Atlanta Gastroenterology Associates
Atlanta, Georgia
Midwest Clinical Research Center
Moline, Illinois
Gastrointestinal Clinic of Quad Cities
Davenport, Iowa
Drug Research Services, Inc.
Metairie, Louisiana
Mayo Clinic
Rochester, Minnesota
Center for Digestive and Liver Diseases, Inc
Mexico, Missouri
New York Center for Clinical Research
Lake Success, New York
ClinSearch
Chattanooga, Tennessee
S D Khan
Houston, Texas
Centro Integral De Gastroenterologia
Ciudad de Buenos Aires, Argentina
Hospital Italiano de Mendoza, FINAMED SA
Mendoza, Argentina
Hospital Italiano de Buenos Aires
Capital Federal, Buenos Aires, Argentina
Bankstown-Lidcombe Hospital
Bankstown, New South Wales, Australia
Concord Hospital
Concord, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Eastern Health Hospital
Box Hill, Victoria, Australia
St Vincent's Hospital
Fitzroy, Victoria, Australia
Fremantle Hospital
Fremantle, Western Australia, Australia
Imelda General Hospital
Bonheiden, Belgium
Ziekenhuis Oost Limburg
Genk, Belgium
Heilig Hart ziekenhuis vzw Roeselare-Menen
Roeselare, Belgium
Unigastro
Castelo, Brazil
Hospital de Clinicas
Porto Alegre, Brazil
Universidade Federal do Rio de Janeiro
Rio de Janeiro, Brazil
Universidade Federal da Bahia - Hospital
Salvador, Brazil
Hospital Sao Paulo
São Paulo, Brazil
Hospital Israelita Albert Einstein
São Paulo, Brazil
GI Research
Edmonton, Canada
University of Calgary
Calgary, Alberta, Canada
Toronto Digestive Disease Associates, Inc.
Toronto, Ontario, Canada
Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Hópital Hótel-Dieu de Quebec
Québec, Quebec, Canada
Hospital del Salvador
Santiago, Chile
Clinica Las Condes
Santiago, Chile
Showing 40 of 142 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.